Stock Alert: Aldeyra Therapeutics Rising On Positive Top-line Results From Reproxalap

(RTTNews) - Shares of Aldeyra Therapeutics, Inc. (ALDX) are climbing more than 10% Thursday morning after the company reported positive top-line results from the phase III study of its lead drug candidate Reproxalap in dry eye disease.

The company reported positive top-line symptom, redness, and Schirmer's test results from the run-in cohort of the Phase III study dubbed Tranquility in patients with dry eye disease.

Improvement in ocular symptoms and redness occurred within minutes after reproxalap dosing. Consistent with clinical experience in more than 1,100 patients, no adverse findings on safety assessments were observed, and reproxalap was well-tolerated, the company said.

The main cohort of Tranquility is expected to begin enrollment in February 2021 with results expected in the second half of 2021.

A second Phase III study dubbed Tranquility-2, is expected to begin in the first quarter of 2021.

ALDX, currently at $7.37, has been trading in the range of $1.48- $8.7 in the last one year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More